Drug intelligence / Profile preview

BL-050

Development stage: Preclinical
Lead developer: Bilayer Therapeutics
Modality: Small Molecules

Overview

BL-050 is a small molecule drug initially developed by Bilayer Therapeutics, Inc. It is under preclinical development primarily for endocrinology and metabolic diseases, with a focus on metabolic disorders. The exact mechanism of action has not been detailed in the available data. The compound appears to be investigated for its potential therapeutic effects related to metabolism and endocrinology.

Beyond the preview

Go deeper on BL-050.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-050.

Explore the full profile